MDMA — Pharmala Biotech Holdings Balance Sheet
0.000.00%
- CA$10.48m
- CA$10.44m
- CA$0.53m
Annual balance sheet for Pharmala Biotech Holdings, fiscal year end - August 31st, CAD millions except per share, conversion factor applied.
2021 August 31st | 2022 August 31st | 2023 August 31st | |
---|---|---|---|
Period Length: | — | — | — |
Source: | PROSPECTUS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS |
Status: | Final | Final | Final |
Cash | |||
Cash and Short Term Investments | 2.47 | 0.852 | 0.195 |
Net Total Accounts Receivable | |||
Net Total Receivables | 0.06 | 0.051 | 0.223 |
Total Inventory | |||
Prepaid Expenses | |||
Total Current Assets | 2.53 | 1.09 | 0.714 |
Gross Property, Plant And Equipment | |||
Accumulated Depreciation | |||
Net Property, Plant And Equipment | 0.002 | 0.004 | 0.002 |
Net Intangible Assets | |||
Total Assets | 2.79 | 2.33 | 2.41 |
Payable / Accrued | |||
Notes Payable / Short Term Debt | |||
Total Other Current Liabilities | |||
Total Current Liabilities | 0.138 | 0.424 | 1.03 |
Total Long Term Debt | |||
Total Debt | |||
Total Liabilities | 0.138 | 0.424 | 1.03 |
Common Stock | |||
Additional Paid In Capital | |||
Retained Earnings (Accumulated Deficit) | |||
Total Equity | 2.66 | 1.91 | 1.38 |
Total Liabilities & Shareholders' Equity | 2.79 | 2.33 | 2.41 |
Total Common Shares Outstanding |